Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (April 2026)
20 slides from Orthocell's investor presentation, Apr 20, 2026
Slide 1: Q3 FY26 Investor Presentation
Q3 FY26 Investor Presentation 20th April 2026
Slide 2: Disclaimer
Disclaimer This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, representations contained in this presentation, and they do not accept any liability or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy whatsoever (including in negligence
Slide 3: Orthocell at a glance
Orthocell at glance Best-in-class platform Product margins Growing International Remplir US Strategy The path to breakeven for Bone, Nerve and retained in-house Revenues Targeting is on-track is clear and achievable Tendon repair Manufacturing facility Large Under Market access activities We have su
Slide 4: Key highlights for the quarter ended March 2026
Key highlights for the quarter ended 31 March 2026 Build global footprint Win in the Continue growth Advance the with collagen Strategic Americas in ANZ and Asia medical devices product pipeline focus • Remplir US key • >300 Australian • Appointment of LEDA • Approximately 200 commercial metrics Sur
Slide 5: Key quarterly metrics
Key quarterly metrics Q3 FY26 delivered strong performance across all six key quarterly metrics. With a now established and growing commercial distribution platform in the U.S., the Company anticipates a material uplift in U.S. revenue in the upcoming quarters. 1. Total Revenue (Group) 2. US Revenue
Slide 6: Q3 FY26 Revenue and cash flow performance
Q3 FY26 Revenue and cash flow performance
Slide 7: Quarterly revenue growth
Quarterly revenue growth US Remplir sales continue to grow quarter on quarter, with $300k revenue for Q3 FY26 representing the first material quarter of sales from the U.S., and Remplir contributing the vast majority of the $2.9M year-to-date growth. Revenue Bridge: Q1–Q3 Total Revenue1 by Quarter (
Slide 8: AU/NZ Performance since launch
AU/NZ Performance since launch1 Significant growth achieved since launch, with near 100% YOY growth, 314 surgeons and 224 hospitals.3 Cumulative Unit Sales1 Unit Sales1 1,000 CQGR2 5,500 +40% 900 5,000 4,500 800 4,000 700 3,500 600 3,000 500 2,500 400 2,000 300 1,500 200 1,000 100 500 0 0 FY23 Q2 FY
Slide 9: Quarterly cash flow summary
Quarterly cash flow summary Sustainable cash reserves are in place to fund the commercialisation of Remplir and support the business to cash flow breakeven, with no additional funding required. AUD $M YTD 3Q26 2Q26 VAR % Net cash flows from operating activities Receipts from customers 5.2 1.6 1.2 0.
Slide 10: Path to profitability (Cashflow Breakeven)
Path to profitability (Cashflow Breakeven) Breakeven1 is achieved at 5,000–6,000 procedures in the US, requiring ~300-400 active surgeons — a number already accessible through the current VAC pipeline. Breakeven Breakeven Profile (1% of market2) <1% U.S. market share required to achieve cash breakev
Slide 11: Q3 FY26 US Remplir launch update
Q3 FY26 US Remplir launch update
Slide 12: US Remplir commercial momentum is building
US Remplir commercial momentum is building TM Exceptional early growth since the first sale of Remplir on 26th June 2025 (9 months). US Remplir Hospitals Cumulative by Quarter1 US Remplir Surgeons Cumulative by Quarter1 US Remplir Unit Sales by Quarter 55 49 115 +275% +264% +328% Q4FY25 Q1FY26 Q2FY2
Slide 13: Areas of Focus to Drive US Remplir Growth
Areas of Focus to Drive US Remplir Growth TM We have three key focus areas to drive U.S. Remplir growth, with clear CY 2026 action plans to continue accelerating adoption. Commercial Channel Hospital Approvals On-board New Surgeons • Five additional distributors • 75 additional VAC submissions • Com
Slide 14: Other achievements and upcoming catalysts
Other achievements and upcoming catalysts
Slide 15: Prostatectomies and Tendon Repair
Prostatectomies and Tendon Repair We are progressing with application expansion into Prostatectomies and general tendon repair. Prostatectomies General Tendon Repair • ~200 surgeries1 now performed with multiple surgeons • SmrtGraft for tendon repair to be continued to be nationwide. supplied in the
Slide 16: Spotlight: Growing Demand for Remplir in Defence
Spotlight 1. 23 soldiers treated in Ukraine - Reinforced unique Growing Demand handling, transportability, and clinical utility. for Remplir TM in Defence New U.S. Department of Defence Approved in 221 military medical approval and a growing number of 2. centres - Enabled existing use cases by milit
Slide 17: Achievements and upcoming catalysts
Achievements Nerve repair, made SMRT and upcoming catalysts1 US first surgical use Achieved US first sales Achieved Appoint further US sales team members Achieved Appoint first and second distributors in CAN Achieved Appoint exclusive distributor in HKG Achieved HK first surgical use Achieved EU+UK
Slide 18: Q&A
Q&A Il \e ortho:c
Slide 19: Appendix - cash flow analysis
Appendix - cash flow analysis Excluding grants, cash outflows were below the three-quarter average across most categories, demonstrating continued operating discipline. AUD $M YTD 3Qavg 3Q26 2Q26 1Q26 QOQ Customer receipts increased 27%, reflecting continued growth in product Receipts from customers
Slide 20: Authorised for release by the Board of Directors
Authorised for release by The Board of Directors of Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com